Lucera Erick
Dyne Therapeutics, Inc. · Chief Financial Officer
Lucera Erick is listed in filings as Chief Financial Officer at Dyne Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 14, 2026, including sale activity. Recent filings connect the profile to Dyne Therapeutics, Inc. (DYN), SAB Biotherapeutics, Inc. (SABS), and Editas Medicine Inc (EDIT). The current snapshot covers public activity from Jul 17, 2024 to May 14, 2026. Reported amounts are shown as $26.6K to $1.7M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $107k5.7k shares | SellApr 1, 2026 | $18.64 | $18.16 | |
| $7.0k4.1k shares | SellMar 4, 2025 | $1.71 | $3.57 |